Wellington Partners

Wellington Partners

  • Home
  • Team
  • Approach
  • Portfolio
  • News
  • Contact

News

Themis starts Phase II clinical study of Chikungunya vaccine in endemic area

  • portfolio-news
Details
Published: 27 July 2017

A promising prophylactic vaccine candidate against Chikungunya fever will be tested from August on in a Phase II clinical study in Puerto Rico, a Chikungunya fever endemic area.  

4SC secures EUR 41 million from successful capital increase

  • portfolio-news
Details
Published: 06 July 2017

4SC AG announced the completion of its capital increase resolved on 12 June 2017 to continue to advance its drug development programs for resminostat, 4SC-202 and 4SC-208. 

Themis starts Phase II trial of Chikungunya vaccine in the U.S.

  • portfolio-news
Details
Published: 06 June 2017

Sponsored by the National Institutes of Health, Themis Bioscience started a Phase II trial of its Chikungunya vaccine on a candidate in the U.S. 

  1. Rigontec starts FIH Phase I/II trial of RIG-I agonist RGT100 & appoints new CMO
  2. Themis launches Zika vaccine clinical trial
  3. Boston Scientific acquires Symetis for USD 435m in cash
  4. Symetis acquires Middle Peak Medical

Page 8 of 17

  • Start
  • Prev
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • Next
  • End
© Wellington Partners, 2019.
  • WP Technology Funds
  • Contact
  • Imprint
  • Privacy